Table 2.
PET variables of target lesions at baseline.
| Characteristic/finding | Value | ||
|---|---|---|---|
| Lesional SUVmax | |||
| Baseline [68Ga]Ga-PSMA-11 PET/CT | |||
| Median (minimum–maximum) | 17.03 (0.35–185.83) | ||
| Mean ± SD | 26.12 ± 29.98 | ||
| Baseline [18F]FDG PET/CT | |||
| Median (minimum–maximum) | 7.94 (2.28–44.00) | ||
| Mean ± SD | 9.95 ± 6.84 | ||
| Baseline FPQ | |||
| Median (minimum–maximum) | 0.51 (0.03–15.54) | ||
| Mean ± SD | 0.99 ± 1.69 | ||
| Category, % of study sample (n) | |||
| ≤ 1 | 73.0% (195/267) | ||
| > 1 | 27.0% (72/267) | ||
| Lesional responsea to RLT, % of study sample (n) | |||
| Partial response | 42.7% (114/267) | ||
| Stable disease | 38.2% (102/267) | ||
| Progression | 19.1% (51/267) | ||
| Non-progressive lesions (n = 216)b | Progressive lesions (n = 51) | p | |
|---|---|---|---|
| SUVmax, baseline [68Ga]Ga-PSMA-11 PET/CT | |||
| Median (minimum–maximum) | 20.77 (1.03–185.80) | 4.48 (0.35–48.25) | < 0.001 |
| Mean ± SD | 30.59 ± 31.45 | 7.19 ± 8.68 | |
| SUVmax, baseline [18F]FDG PET/CT | |||
| Median (minimum–maximum) | 8.15 (2.28–44.00) | 6.90 (3.69–27.37) | 0.289 |
| Mean ± SD | 10.22 ± 7.11 | 8.79 ± 5.47 | |
| FPQ, baseline PET/CT scans | |||
| Median (minimum–maximum) | 0.40 (0.03–3.81) | 1.36 (0.51–15.54) | < 0.001 |
| Mean ± SD | 0.60 ± 0.63 | 2.65 ± 3.16 | |
18F fluorine-18, 68Ga gallium-68, CT computed tomography, FDG fluorodeoxyglucose, FPQ [18F]FDG/[68Ga]Ga-PSMA-11 SUVmax quotient, PET positron emission tomography, PSMA prostate-specific membrane antigen, RLT radioligand therapy, SD standard deviation, SUVmax maximum standardized uptake value.
p values in bold were statistically significant at p < 0.05.
aLesional response classifications are based on change from baseline to post-2nd cycle of RLT in [18F]FDG SUVmax, utilizing PERCIST 1.0 criteria37.
b“Non-progressing lesions” include those showing partial response (n = 114, 52.8% of non-progressing lesions) or stable disease (n = 102, 47.2% of non-progressing lesions).